Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation-Reference-Cited by-同舟云学术

Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation

Published:1998-10 Issue:9134 Volume:352 Page:1087-1092
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Gratwohl A,Hermans J,Goldman JM,Arcese W,Carreras E,Devergie A,Frassoni F,Gahrton G,Kolb HJ,Niederwieser D,Ruutu T,Vernant JP,de Witte T,Apperley J

Publisher

Elsevier BV

Subject

General Medicine

Reference25 articles.

1. Chronic myelogenous leukemia: a review;Cortes;Am J Med,1996

2. New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia;Carella;Haematologica,1997

3. Interferon alpha produces sustained cytogenetic responses in chronic myelogenous leukemia;Talpaz;Ann Intern Med,1991

4. Interferon alpha-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia;N Engl J Med,1994

5. Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II);Hehlmann;Bone Marrow Transplant,1996

Cited by 546 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and Validation of a Concise Objectifiable Risk Evaluation Score for Non-Relapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation;Cancers;2024-01-25

2. Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: a prospective study;Journal for ImmunoTherapy of Cancer;2024-01

3. The Impact of Pretransplant Use of Tyrosine Kinase Inhibitors on Allogeneic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia-A Single-institution Retrospective Study-;Internal Medicine;2024

4. Hematopoietic Transplantation: Past, Present, and Future;Manual of Hematopoietic Cell Transplantation and Cellular Therapies;2024

5. Graft-versus-Host Disease Prophylaxis with Post- Transplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT);Transplantation and Cellular Therapy;2024-01